Five of the world’s biggest drugs companies have agreed to slash the price of
their anti-HIV drugs in developing countries by 85 per cent following sustained
pressure from health agencies, Third World governments and patient groups
(91av, 29 April, p 14).
One of the companies, Glaxo Wellcome, is
cutting the price of triple drug therapy from $16 to $2 a day. But
pressure groups have warned that even at these prices, poverty and a lack of
health infrastructure in poor countries will mean the benefits are limited.
To continue reading, today with our introductory offers
Advertisement
More from 91av
Explore the latest news, articles and features
Popular articles
Trending 91av articles
1
There has been a sudden increase in the rate of sea level rise
2
Man destined for Alzheimer's may have been saved by accidental therapy
3
PCOS postpones perimenopause and allows pregnancies at older ages
4
Dating over 50 is probably on the rise – but we know little about it
5
Fire is spreading in the Chernobyl exclusion zone after drone crash
6
Red-light therapy does have health benefits but not the ones you think
7
A lost ancient script reveals how writing as we know it really began
8
Neanderthal 'kneeprint' found next to mysterious stalagmite circle
9
The monstrous number sequences that break the rules of mathematics
10
Woman in cancer remission without treatment in highly unusual case
